Peringatan Keamanan

Toxicity information regarding teplizumab is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as serious infections, lymphopenia and cytokine release syndrome.L44091 Symptomatic and supportive measures are recommended. The mutagenic and carcinogenic potential of teplizumab has not been evaluated. As an antibody, teplizumab is not expected to interact directly with DNA. In female and male mice, teplizumab did not have significant effects in fertility and reproductive performance when administered subcutaneously at doses up to 20 mg/kg.L44091

Teplizumab

DB06606

biotech approved investigational

Deskripsi

Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D).A241480,A241045,A241475,L44091 T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic ? cells leads to loss of insulin production, impaired glycemic control, and reliance on exogenous insulin.A241490 Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients.A241480,A241500 Targeting T cells can be achieved through antibodies against the T cell receptor (TCR) component CD3. Although the mechanism of action of teplizumab has not been fully elucidated, it may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes.L44091 Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and lead to severe adverse effects related to cytokine release syndrome (CRS). Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS.A241480 On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes.L44096

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) In a 60 kg subject, teplizumab has a mean terminal elimination half-life of 4.5 days.[L44091]
Volume Distribusi In a 60 kg subject, teplizumab has a central volume of distribution (Vd) of 2.27 L.[L44091]
Klirens (Clearance) In a 60 kg subject, teplizumab has a clearance of 2.7 L/day.[L44091]

Absorpsi

During the 14-day treatment course of teplizumab, steady-state concentrations are not expected to be achieved.L44091

Metabolisme

As a monoclonal antibody, teplizumab is expected to be metabolized into small peptides by proteases throughout the body.L44091

Rute Eliminasi

Teplizumab showed saturable binding and elimination.L44091

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Teplizumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Teplizumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Teplizumab.
Estrone Estrone may increase the thrombogenic activities of Teplizumab.
Estradiol Estradiol may increase the thrombogenic activities of Teplizumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Teplizumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Teplizumab.
Mestranol Mestranol may increase the thrombogenic activities of Teplizumab.
Estriol Estriol may increase the thrombogenic activities of Teplizumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Teplizumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Teplizumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Teplizumab.
Tibolone Tibolone may increase the thrombogenic activities of Teplizumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Teplizumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Teplizumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Teplizumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Teplizumab.
Zeranol Zeranol may increase the thrombogenic activities of Teplizumab.
Equol Equol may increase the thrombogenic activities of Teplizumab.
Promestriene Promestriene may increase the thrombogenic activities of Teplizumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Teplizumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Teplizumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Teplizumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Teplizumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Teplizumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Teplizumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Teplizumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Teplizumab.
Formononetin Formononetin may increase the thrombogenic activities of Teplizumab.
Estetrol Estetrol may increase the thrombogenic activities of Teplizumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Teplizumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Teplizumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Teplizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Teplizumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Teplizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teplizumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Teplizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Teplizumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Teplizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Teplizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Teplizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Teplizumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Teplizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teplizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Teplizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teplizumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Teplizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Teplizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teplizumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Teplizumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Teplizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Teplizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teplizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Teplizumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Teplizumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Teplizumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Teplizumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Teplizumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Teplizumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Teplizumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Teplizumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Teplizumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Teplizumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Teplizumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Teplizumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Teplizumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Teplizumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Teplizumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Teplizumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Teplizumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Teplizumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Teplizumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Teplizumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Teplizumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Teplizumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Teplizumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Teplizumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Teplizumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Teplizumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Teplizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Teplizumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Teplizumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Teplizumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Teplizumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Teplizumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Teplizumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Teplizumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Teplizumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Teplizumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Teplizumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Teplizumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Teplizumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Teplizumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Teplizumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Teplizumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Teplizumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Teplizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Teplizumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Teplizumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Teplizumab.

Target Protein

T-cell surface glycoprotein CD3 epsilon chain CD3E

Referensi & Sumber

Synthesis reference: Koenig, S, et al. (2014). Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity. (U.S. Patent No. 8,663,634 B2). U.S. Patent and Trademark Office. https://patentimages.storage.googleapis.com/53/4f/2f/7b8a017220d8b8/US8663634.pdf
Artikel (PubMed)
  • PMID: 31533907
    Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC: Changing the landscape for type 1 diabetes: the first step to prevention. Lancet. 2019 Oct 5;394(10205):1286-1296. doi: 10.1016/S0140-6736(19)32127-0. Epub 2019 Sep 15.
  • PMID: 33418839
    Felton JL, Conway H, Bonami RH: B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes. Biomedicines. 2021 Jan 6;9(1). pii: biomedicines9010042. doi: 10.3390/biomedicines9010042.
  • PMID: 31523950
    Gaglia J, Kissler S: Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance. Biochemistry. 2019 Oct 8;58(40):4107-4111. doi: 10.1021/acs.biochem.9b00707. Epub 2019 Sep 24.
  • PMID: 33459118
    Kaplon H, Reichert JM: Antibodies to watch in 2021. MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476.
  • PMID: 10716879
    Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA: In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000 Feb 25;200(1):16-26. doi: 10.1006/cimm.2000.1617.
  • PMID: 31180194
    Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9.
  • PMID: 31157632
    Linsley PS, Long SA: Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D. Curr Opin Endocrinol Diabetes Obes. 2019 Aug;26(4):213-218. doi: 10.1097/MED.0000000000000488.
  • PMID: 26518356
    Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K, Ehlers MR, McNamara JG, Harris KM, Kanaparthi S, Phippard D, Herold KC: Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur J Immunol. 2016 Jan;46(1):230-41. doi: 10.1002/eji.201545708. Epub 2015 Dec 14.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 1 • International brands: 1
Produk
  • Tzield
    Injection • 1 mg/1mL • Intravenous • US • Approved
International Brands
  • Tzield — Provention Bio, Inc

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul